ClinicalTrials.gg
Active, not recruitingNCT07216079Updated Nov 10, 2026

Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan

A Phase 3 interventional study of rilzabrutinib in Immune Thrombocytopenia, sponsored by Sanofi. Active, not recruiting at 3 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Updated Nov 10, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan — 6 open to participants now, 10 under way, 7 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Japan.

Enrollment
21st of 21
3 · median 105
Started
2025
with 3 others
Phase 3
16 of 23
2 open now
Registered
23rd of 23
by date
Lead sponsor
1 of 23
Sanofi

Among the 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan, this one is the 21st largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2025, is one of 16 in phase 3, and was the 23rd registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

6 of the 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan, or all of them as a file.
02

Study summary

This is an open-label, multi-center, single group, Phase 3 study for treatment with rilzabrutinib.

The purpose of this study is to provide continuation of rilzabrutinib treatment to adult participants with ITP who have completed the LTE of the LUNA 3 study in Japan, demonstrating clinically meaningful benefit as judged by the Investigator.

03

Conditions studied

  • Immune Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have been enrolled in and have completed the LTE of the LUNA 3 study with demonstration of efficacy without major safety concern while on study considered by the Investigator to be .
  • Participants who have ongoing diagnosis of primary ITP and continue to require treatment for ITP according to the Investigator.
  • Participants who have acceptable benefit/risk profile.
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Participants with secondary ITP.
  • Pregnant or lactating women.
  • (ECG) findings for participants. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Rilzabrutinib

    400 mg

    Drug: rilzabrutinib

Interventions

  • Pharmaceutical form:Tablet-Route of administration:Oral

    Also known as: SAR444671

06

What researchers measure

Primary outcomes

  1. AEs including SAEs and AESIs

    An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor is required

    Time frame: Until study completion, approximately 60 weeks

07

Study locations

3 sites
  • Investigational Site Number: 1001
    Tsuchiura, Ibaraki 300-0028, Japan
  • Investigational Site Number: 1002
    Kanazawa, Ishikawa-ken 920-8641, Japan
  • Investigational Site Number: 1003
    Iruma-gun, Saitama 350-0495, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2026, 13 months after the start.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's planned 13 months is below that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2025
First posted
Oct 14, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Nov 25, 2026
CompletionEst.
Nov 25, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 30, 2026→Nov 25, 2026
Nov 10, 2026
Study completion
Nov 30, 2026→Nov 25, 2026
Nov 10, 2026
Enrollment
4 (estimated)→3 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Nov 30, 2026→Nov 25, 2026
    Study completion Nov 30, 2026→Nov 25, 2026
    Enrollment 4 (estimated)→3 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07216079
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 14, 2025
Start date
Oct 15, 2025
Primary completion
Nov 25, 2026 (estimated)
Completion
Nov 25, 2026 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion